Multiple myeloma  patients experience high  response rate with new  three-drug combination.  [electronic resource] 

 -  Cancer biology & therapy  Dec 2009 
 - ii-iii p.  digital 
<br/><br/> Publication Type: News 
<br/><br/><label>ISSN: </label>1555-8576 
<br/><br/><label>Standard No.: </label>10.4161/cbt.8.24.11003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bone Marrow--pathology<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Clinical Trials, Phase I as Topic<br/>Clinical Trials, Phase II as Topic<br/>Dexamethasone--administration & dosage<br/>Disease-Free Survival<br/>Drug Administration Schedule<br/>Humans<br/>Lenalidomide<br/>Leukocytes--pathology<br/>Multicenter Studies as Topic<br/>Multiple Myeloma--drug therapy<br/>Pyrazines--administration & dosage<br/>Stem Cell Transplantation<br/>Thalidomide--administration & dosage<br/>Treatment Outcome